| Gene Symbol | SLC17A7 |
| Full Name | Solute Carrier Family 17 Member 7 |
| Chromosome | 19q13.33 |
| Protein Type | Transporter |
| Target Class | Transporter |
| Function | Expression restoration — upregulating SLC17A7 transcription or stabilizing VGLUT1 protein to preserve excitatory synaptic function |
| Mechanism of Action | Expression restoration — upregulating SLC17A7 transcription or stabilizing VGLUT1 protein to preserve excitatory synaptic function |
| Primary Expression | thalamocortical neurons and subpopulations of cortical and hippocampal neurons |
| Druggability | Medium (0.53) |
| Clinical Stage | Phase III |
| Molecular Weight | 65 kDa |
| Pathways | Amyloid, Apoptosis, Excitability, Excitatory synaptic transmission, Insulin signalling |
| UniProt ID | Q9P2U8 |
| NCBI Gene ID | 8703 |
| Ensembl ID | ENSG00000177508 |
| GeneCards | SLC17A7 |
| Human Protein Atlas | SLC17A7 |
| Associated Diseases | ALS, Alzheimer's Disease, Cancer, Epileptogenesis |
| Known Drugs/Compounds | Riluzole, Troriluzole, Chicago Sky Blue 6B |
| Interactions | VGLUT1, KDM6B, SLC17A6, TAU, VGLUT2, SYNAPTOPHYSIN |
| SciDEX Target | View Target Profile (8 clinical trials) |
| SciDEX Hypotheses | Layer V excitatory neurons show selectively enhanc Excitatory Neuron Vulnerability via SLC17A7 Downre |
| KG Connections | 376 knowledge graph edges |
| Databases | GeneCardsHPASTRING |